Trial Information

Summary: Atopic Dermatitis

A Randomized, Double blind, placebo controlled, parallel group study of the safety and efficacy of 1% and 2% Nanocrystalline Silver cream ( NPI 32101) applied twice daily in Pediatric and adolescent subjects with mild to moderate atopic dermatitis(AD)

Inclusion Criteria:

  • Age- 2 to 17 years
  • Mild to moderate atopic dermatitis
  • Body surface area involved must be between 5 and 40%

Contact:

Hirak B. Routh, MBBS
Paddington Testing Co., Inc
1760 Market Street
Suite 301
Philadelphia, PA 19103
Telephone: 215 563 7330
Fax: 215 563 9405
Email:

Profile Page: Paddington Testing Co., Inc, Philadelphia, PA

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:18 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA